Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide
Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
1. A method of preparing a mammalian oocyte for in vitro fertilization, comprising:
contacting an oocyte with a soluble hyaluronidase polypeptide; and
removing the cumulus matrix, wherein:
the soluble hyaluronidase polypeptide comprises at least one sugar moiety that is covalently attached to an asparagine residue of the soluble hyaluronidase polypeptide;
the soluble hyaluronidase polypeptide is catalytically active at neutral pH; and
the soluble hyaluronidase polypeptide either:
(i) consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1; or
(ii) comprises amino acid substitutions in the amino sequences of 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, and
wherein the soluble hyaluronidase polypeptide with the substitutions has at least 95% amino acid sequence identity with the sequence of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.
2. The method of claim 1 , wherein the cumulus matrix is removed prior to cryopreservation of the oocytes.
3. The method of claim 1 , wherein the in vitro fertilization comprises intracytoplasmic sperm injection (ICSI).
4. The method of claim 1 , comprising:
adding the soluble hyaluronidase polypeptide to harvested oocytes;
separating the oocytes from the released cumulus cells through aspiration; and
washing the resulting oocytes with medium that does not comprise the soluble hyaluronidase polypeptide.
5. The method of claim 4 , further comprising processing the oocytes for cryopreservation or for in vitro fertilization.
6. The method of claim 1 , wherein the soluble hyaluronidase polypeptide consists of the sequence of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO: 1.
7. A method of preparing a mammalian oocyte for in vitro fertilization, comprising:
contacting an oocyte with a soluble hyaluronidase polypeptide in an effective amount to remove the cumulus matrix, wherein:
the soluble hyaluronidase polypeptide comprises at least one sugar moiety that is covalently attached to an asparagine residue of the soluble hyaluronidase polypeptide;
the soluble hyaluronidase polypeptide is catalytically active at neutral pH; and
the soluble hyaluronidase polypeptide has at least 98% sequence identity with the sequence of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO: 1.
8. The method of claim 1 , wherein:
the soluble hyaluronidase polypeptide comprises at least one sugar moiety that is covalently attached to an asparagine residue of the soluble hyaluronidase polypeptide;
the soluble hyaluronidase polypeptide is catalytically active at neutral pH; and
the soluble hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% amino acid sequence identity with the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO: 1.
9. A method of preparing a mammalian oocyte for in vitro fertilization, comprising:
contacting an oocyte with a soluble hyaluronidase polypeptide in an amount effective for removing the cumulus matrix to thereby remove the cumulus matrix, wherein:
the soluble hyaluronidase polypeptide comprises at least one sugar moiety that is covalently attached to an asparagine residue of the soluble hyaluronidase polypeptide;
the soluble hyaluronidase polypeptide is catalytically active at neutral pH; and consists of an amino sequence set forth in any of a)-d):
a) an amino acid that consists of a contiguous sequence within SEQ ID NO:1 that comprises amino acids 36-464 of SEQ ID NO:1 and that is truncated within the C-terminal region of SEQ ID NO:1 so that it does not comprise the full-length of SEQ ID NO:1, wherein the truncation is at a residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1;
b) the sequence of amino acids in a) with amino acid substitutions wherein the amino acid sequence of a) is at least 91% identical to amino acids 36-464 of SEQ ID NO: 1;
c) the amino acid sequence in a) having at least 99% sequence identity to amino acids 36-464 of SEQ ID NO: 1; and
d) the amino sequence in a) having at least 98% sequence identity to amino acids 36-464 of SEQ ID NO: 1, wherein the C-terminus terminates at residue 483.
10. The method of claim 8 , wherein the asparagine residue is selected from amino acids 82, 166, 235, 254, 368, and 393 by alignment with SEQ ID NO:1.
11. The method of claim 9 , wherein the asparagine residue is selected from amino acids 82, 166, 235, 254, 368, and 393 by alignment with SEQ ID NO:1.
12. The method of claim 1 , wherein the soluble hyaluronidase polypeptide is modified with a polymer.
13. The method of claim 12 , wherein the polymer is polyethylene glycol (PEG) or dextran.